Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGEM Cullinan Therapeutics	$7.67 +2.7%	$7.80	$6.85 ▼ $19.89	$441.29M	-0.08	359,773 shs	296,078 shs
ETON Eton Pharmaceuticals	$17.09 +3.3%	$14.94	$4.12 ▼ $21.48	$443.83M	1.13	364,619 shs	231,314 shs
TNXP Tonix Pharmaceuticals	$35.85 -0.6%	$41.36	$6.76 ▼ $130.00	$316.01M	1.7	2.21 million shs	1.10 million shs
ZNTL Zentalis Pharmaceuticals	$1.87 +14.0%	$1.39	$1.01 ▼ $5.44	$118.30M	1.71	636,034 shs	2.62 million shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGEM Cullinan Therapeutics	-1.45%	-2.23%	-0.66%	-5.32%	-57.58%
ETON Eton Pharmaceuticals	+2.16%	-3.33%	+14.93%	-18.27%	+301.70%
TNXP Tonix Pharmaceuticals	-1.31%	-41.45%	-20.07%	+36.55%	-5.13%
ZNTL Zentalis Pharmaceuticals	+3.14%	+10.07%	+17.99%	+32.26%	-47.77%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CGEM Cullinan Therapeutics	1.7157 of 5 stars	3.5	0.0	1.7	1.7	0.6
ETON Eton Pharmaceuticals	2.3958 of 5 stars	3.5	1.0	3.1	1.7	0.6
TNXP Tonix Pharmaceuticals	2.6867 of 5 stars	3.5	2.0	3.1	1.7	0.6
ZNTL Zentalis Pharmaceuticals	1.7892 of 5 stars	3.3	2.0	2.2	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CGEM Cullinan Therapeutics	3.00	Buy	$26.80	249.41% Upside
ETON Eton Pharmaceuticals	3.00	Buy	$29.67	73.59% Upside
TNXP Tonix Pharmaceuticals	3.00	Buy	$70.00	95.26% Upside
ZNTL Zentalis Pharmaceuticals	2.67	Moderate Buy	$8.20	338.50% Upside

Current Analyst Ratings Breakdown

Latest ZNTL, ETON, CGEM, and TNXP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2025	CGEM Cullinan Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$24.00
8/18/2025	CGEM Cullinan Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$35.00 ➝ $28.00
8/7/2025	ZNTL Zentalis Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/7/2025	ZNTL Zentalis Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$6.00 ➝ $5.00
6/11/2025	CGEM Cullinan Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$22.00
6/3/2025	TNXP Tonix Pharmaceuticals	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/29/2025	ETON Eton Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$33.00 ➝ $35.00

(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CGEM Cullinan Therapeutics	N/A	N/A	N/A	N/A	$8.33 per share	N/A
ETON Eton Pharmaceuticals	$39.01M	11.75	N/A	N/A	$0.89 per share	19.20
TNXP Tonix Pharmaceuticals	$10.09M	31.16	N/A	N/A	$19.17 per share	1.87
ZNTL Zentalis Pharmaceuticals	$67.43M	2.00	N/A	N/A	$3.81 per share	0.49

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CGEM Cullinan Therapeutics	-$167.38M	-$3.23	N/A	N/A	N/A	N/A	-36.56%	-34.82%	11/6/2025 (Estimated)
ETON Eton Pharmaceuticals	-$3.82M	-$0.16	N/A	34.18	N/A	-7.10%	-0.73%	-0.22%	N/A
TNXP Tonix Pharmaceuticals	-$130.04M	-$39.47	N/A	N/A	N/A	-828.22%	-57.93%	-51.04%	N/A
ZNTL Zentalis Pharmaceuticals	-$165.84M	-$2.26	N/A	N/A	N/A	N/A	-51.62%	-40.28%	N/A

Latest ZNTL, ETON, CGEM, and TNXP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q1 2025	TNXP Tonix Pharmaceuticals	-$3.10	-$3.86	-$0.76	-$3.86	$2.60 million	$2.00 million
8/7/2025	Q2 2025	CGEM Cullinan Therapeutics	-$0.83	-$1.07	-$0.24	-$1.07	N/A	N/A
8/7/2025	Q2 2025	ETON Eton Pharmaceuticals	-$0.01	-$0.10	-$0.09	-$0.10	$16.71 million	$18.93 million
8/6/2025	Q2 2025	ZNTL Zentalis Pharmaceuticals	-$0.56	-$0.37	+$0.19	-$0.37	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CGEM Cullinan Therapeutics	N/A	N/A	N/A	N/A	N/A
ETON Eton Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TNXP Tonix Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ZNTL Zentalis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CGEM Cullinan Therapeutics	N/A	9.83	9.83
ETON Eton Pharmaceuticals	1.14	1.77	1.16
TNXP Tonix Pharmaceuticals	N/A	7.53	7.22
ZNTL Zentalis Pharmaceuticals	N/A	7.99	7.99

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CGEM Cullinan Therapeutics	86.31%
ETON Eton Pharmaceuticals	27.86%
TNXP Tonix Pharmaceuticals	82.26%
ZNTL Zentalis Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
CGEM Cullinan Therapeutics	7.16%
ETON Eton Pharmaceuticals	16.03%
TNXP Tonix Pharmaceuticals	0.03%
ZNTL Zentalis Pharmaceuticals	1.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CGEM Cullinan Therapeutics	30	59.07 million	54.84 million	Optionable
ETON Eton Pharmaceuticals	20	26.82 million	22.52 million	Optionable
TNXP Tonix Pharmaceuticals	50	8.77 million	8.76 million	Not Optionable
ZNTL Zentalis Pharmaceuticals	160	72.14 million	70.76 million	Optionable

ZNTL, ETON, CGEM, and TNXP Headlines

Recent News About These Companies

Guggenheim Remains a Buy on Zentalis Pharmaceuticals (ZNTL)

August 19 at 7:30 AM | theglobeandmail.com

Zentalis Pharmaceuticals (ZNTL) Gets a Buy from TD Cowen

August 18 at 9:03 AM | theglobeandmail.com

Zentalis (ZNTL) Q2 Loss Narrows 70%

August 18 at 4:02 AM | theglobeandmail.com

Wedbush Issues Positive Outlook for ZNTL Earnings

August 12, 2025 | americanbankingnews.com

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Stock Rating Upgraded by Wall Street Zen

August 11, 2025 | americanbankingnews.com

Leerink Partnrs Has Pessimistic View of ZNTL Q3 Earnings

August 11, 2025 | marketbeat.com

Equities Analysts Offer Predictions for ZNTL Q3 Earnings

August 11, 2025 | marketbeat.com

HC Wainwright Upgrades Zentalis Pharmaceuticals (NASDAQ:ZNTL) to "Strong-Buy"

August 10, 2025 | marketbeat.com

Wall Street Zen Upgrades Zentalis Pharmaceuticals (NASDAQ:ZNTL) to Hold

August 10, 2025 | marketbeat.com

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Releases Earnings Results

August 9, 2025 | marketbeat.com

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Sold by Primecap Management Co. CA

August 9, 2025 | marketbeat.com

Zentalis price target lowered to $5 from $6 at Wells Fargo

August 8, 2025 | msn.com

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Price Target Cut to $5.00 by Analysts at Wells Fargo & Company

August 8, 2025 | marketbeat.com

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Bought by Federated Hermes Inc.

August 7, 2025 | marketbeat.com

Zentalis Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Progress

August 6, 2025 | globenewswire.com

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average Recommendation of "Moderate Buy" by Brokerages

August 6, 2025 | marketbeat.com

GSA Capital Partners LLP Boosts Holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

August 3, 2025 | marketbeat.com

Zentalis Pharmaceuticals (ZNTL) Projected to Post Quarterly Earnings on Friday

August 1, 2025 | marketbeat.com

Decheng Capital LLC Lowers Stock Holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

July 30, 2025 | marketbeat.com

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) is favoured by institutional owners who hold 59% of the company

July 24, 2025 | finance.yahoo.com

Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

July 1, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZNTL, ETON, CGEM, and TNXP Company Descriptions

Cullinan Therapeutics NASDAQ:CGEM

$7.67 +0.20 (+2.68%)

Closing price 04:00 PM Eastern

Extended Trading

$7.67 0.00 (-0.01%)

As of 05:26 PM Eastern

Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Eton Pharmaceuticals NASDAQ:ETON

$17.09 +0.54 (+3.26%)

Closing price 04:00 PM Eastern

Extended Trading

$17.52 +0.43 (+2.49%)

As of 07:53 PM Eastern

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

Tonix Pharmaceuticals NASDAQ:TNXP

$35.85 -0.20 (-0.55%)

Closing price 04:00 PM Eastern

Extended Trading

$36.11 +0.26 (+0.72%)

As of 07:59 PM Eastern

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey.

Zentalis Pharmaceuticals NASDAQ:ZNTL

$1.87 +0.23 (+14.02%)

Closing price 04:00 PM Eastern

Extended Trading

$1.88 +0.00 (+0.27%)

As of 07:52 PM Eastern

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time